ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0553 • ACR Convergence 2021

    IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study

    Aurélien Chepy1, Solange Vivier2, Fabrice Bray3, Martin Figeac4, Jean-Pascal Meneboo4, Camille Ternynck5, Lucile Guilbert2, Manel Jendoubi2, Christian Rolando3, David Launay1, Sylvain Dubucquoi6, Guillemette Marot5 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, 2Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille, France, 3Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse, l'Analyse et la Protéomique, F-59000 Lille, France, Lille, France, 4Université de Lille, Functional Genomics Platform, Lille, France., Lille, France, 5ULR 2694 – METRICS : évaluation des technologies de santé et des pratiques médicales, université de Lille, CHU de Lille, 59000 Lille, France, Lille, France, 6Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille

    Background/Purpose: Antinuclear antibodies are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is much more debated. This study explored the…
  • Abstract Number: 0552 • ACR Convergence 2021

    Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis

    Francesca Tirelli1, Elena Pachera1, Robert Lafyatis2, Menqi Huang3, Francesco Zulian4, Gabriela Kania1 and Oliver Distler5, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology Unit, Department of Woman and Child Health - University of Padova, Padova, Italy, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland

    Background/Purpose: Long non-coding RNAs (lncRNAs) are non-coding transcripts involved in the regulation of gene expression; their role in disease development, to date, remains largely under…
  • Abstract Number: 0547 • ACR Convergence 2021

    Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells

    Ross Penglase, Malini Visweswaran, John Zaunders, Laila Girgis, David Ma and John Moore, St Vincent's Hospital, Sydney, Australia

    Background/Purpose: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is an effective treatment for severe systemic sclerosis (SSc). To date, mechanistic studies have indicated possible pro-regulatory and…
  • Abstract Number: 0558 • ACR Convergence 2021

    The Systemic Sclerosis (SSc) Risk Gene A20 (TNFAIP3) and Its Repressor DREAM Determine Susceptibility to Fibrosis

    Swarna Bale1, Wenxia Wang2, Roberta G Marangoni3, Erica Herzog4, Bettina C Schock5, Swati Bhattacharyya1 and Varga John1, 1University of Michigan, Ann Arbor, MI, 2Northwestern University, Chicago, IL, 3University of Rochester, Rochester, NY, 4Yale University School of Medicine, New Haven, CT, 5Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom

    Background/Purpose: The ubiquitin-editing enzyme A20, encoded by TNFAIP3, is genetically implicated in autoimmune and inflammatory diseases. A20 plays a pivotal role in regulating inflammatory cellular…
  • Abstract Number: 0557 • ACR Convergence 2021

    The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

    Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
  • Abstract Number: 0555 • ACR Convergence 2021

    Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data

    Dillon Popovich1, Tamar Abel1, Noelle Kosarek2, Monica Espinoza3, Rezvan Parvizi4, Jonathan Garlick5 and Michael Whitfield4, 1Geisel School of Medicine, West Lebanon, NH, 2Dartmouth Geisel School of Medicine, Hartford, VT, 3Geisel School of Medicine, Hanover, NH, 4Geisel School of Medicine, Lebanon, NH, 5Tufts University School of Dental Medicine, Boston, MA

    Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…
  • Abstract Number: 0559 • ACR Convergence 2021

    Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis

    M.Asif Amin1, Bo Shi2, Pei-Suen Tsou1, Swarna Bale1, Phillip Campbell1, Mikel Gurrea-Rubio1, Mark Eckert3, Ernst Lengyel3, Johann Gudjonsson4 and Varga John1, 1University of Michigan, Ann Arbor, MI, 2Nothwestern university, Chicago, IL, 3University of chicago, Chicago, IL, 4Department of Dermatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Fibrosis, the hallmark of systemic sclerosis (SSc), is associated with metabolic and epigenetic alterations that are incompletely characterized. Our laboratory had previously implicated dysregulated…
  • Abstract Number: 0561 • ACR Convergence 2021

    Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports

    Brent Luedders1, Brendan Cope2, Matt Devries2, W. Scott Campbell2, James Campbell2, Ted Mikuls3, Jeffrey Curtis4, Daniel Hershberger3 and Bryant England3, 1University of Nebraska Medical Center, Omaha, NE, United Kingdom, 2University of Nebraska Medical Center, Omaha, 3University of Nebraska Medical Center, Omaha, NE, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…
  • Abstract Number: 0560 • ACR Convergence 2021

    Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study

    Klaus Krüger1, Frank Behrens2, Ulrich Prothmann3, Thilo Klopsch4, Lisa Blindzellner5, Olaf Behmer5, Jürgen Jobst5, Pascal Klaus5, Thomas Meng5 and Peter-Andreas Löschmann5, 1Rheumatological Practice Center, Munich, Germany, 2CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, 3Knappschaftsklinikum Saar, Püttlingen, Germany, 4Rheumatological Practice, Neubrandenburg, Germany, 5Pfizer Pharma GmbH, Berlin, Germany

    Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…
  • Abstract Number: 0556 • ACR Convergence 2021

    Investigating the Heterogeneity of Skin Macrophages in Systemic Scleroderma

    Hadijat Makinde1, Salina Dominguez1, Monique Hinchcliff2, Deborah Winter3 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Yale School of Medicine, Westport, CT, 3Northwestern University Division of Rheumatology, Chicago, IL

    Background/Purpose: The etiology and pathogenesis of systemic sclerosis (SSc) are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes…
  • Abstract Number: 0550 • ACR Convergence 2021

    Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension

    Hilde Jenssen Bjørkekjær1, Håvard Fretheim2, Helene Marjavara Inselseth3, Øyvind Midtvedt4, Imon Barua4, Torhild Garen5, Helle Bitter1, Arne Andreassen6, Øyvind Molberg4, Kaspar Broch6 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, 2Oslo University Hospital, Oslo, Norway, 3University of Oslo, Oslo, Norway, 4Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 5Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, 6Department of Cardiology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). It is associated with impaired quality of life and high mortality.…
  • Abstract Number: 0531 • ACR Convergence 2021

    Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics

    Asmaa AbuMaziad1, Abhimanyu Amarnani2 and Ram Singh3, 1University of California Los Angeles, Los Angeles, CA, 2Los Angeles County + University of Southern California, Los Angeles, CA, 3University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
  • Abstract Number: 0502 • ACR Convergence 2021

    Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms

    Benjamin Hur1, Matthew Koster1, Jin Sung Jang1, Kenneth Warrington2 and Jaeyun Sung1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
  • Abstract Number: 0439 • ACR Convergence 2021

    Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer

    Amy Cunningham-Bussel1, Jiaqi Wang2, Lauren Prisco3, Lily Martin2, Kathleen Vanni2, Alessandra Zaccardelli2, Mazen Nasrallah4, Lydia Gedmintas2, Lindsey MacFarlane5, Nancy Shadick6, Mark M. Awad7, Osama E. Rahma7, Nicole LeBoeuf8, Ellen Gravallese9 and Jeffrey Sparks2, 1Brigham and Women's, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Pound Ridge, MA, 4MGH, Somerville, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham & Women's Hospital, Boston, MA, 7Dana-Farber Cancer Institute, Boston, 8Brigham and Women's Hospital, Department of Dermatology, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
  • Abstract Number: 0314 • ACR Convergence 2021

    PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome

    Dana DiRenzo1, Susan Robinson2, Clifton Bingham1, Alan Baer3 and Thomas Grader-Beck1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR)…
  • « Previous Page
  • 1
  • …
  • 587
  • 588
  • 589
  • 590
  • 591
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology